131 results
Page 3 of 7
6-K
EX-99.1
h9g uqtavh7
8 Mar 22
Current report (foreign)
8:49am
6-K
EX-99.1
r7805
15 Feb 22
Current report (foreign)
4:27pm
6-K
EX-1.1
jpzfv06ai8pmi2 6l6j
11 Feb 22
Current report (foreign)
5:29pm
424B5
xa0sj stqqw5y
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.1
2mb1gy72wenta70bzg
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.1
qwaro75i7u04
17 Sep 21
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to
7:36am
6-K
EX-99.2
xwl juv5z7p6
2 Sep 21
Notice of Annual General Meeting of Shareholders
7:20am
6-K
EX-99.1
bbbwxty fuug
30 Aug 21
Current report (foreign)
7:50am
6-K
vztzquzhukhrlfa
16 Aug 21
Current report (foreign)
7:00am
6-K
EX-99.1
zvcxq
8 Jul 21
VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
4:05pm
6-K
EX-99.1
vtro2uxt5b2kvwlep1
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
6-K
EX-99.1
alukfspy5gkydae
4 Jun 21
Current report (foreign)
8:05am
6-K
ecdluo0htaati5q
11 May 21
Current report (foreign)
7:00am
POS AM
bz7pcxpm te
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm
424B8
buqgszivuppf7r1jg9kv
19 Apr 21
Prospectus unintentially filed late
5:06pm
6-K
EX-1.1
2f91 954m40x7
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
6-K
EX-4.1
a53y2x 5t4un2zdka
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
424B5
pchsw pfmzrhnhxk
12 Apr 21
Prospectus supplement for primary offering
9:07am